Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 420

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities

Open access
Calses, Philamer C., Crawford, James J., Lill, Jennie R., Dey, Anwesha·2019·Trends in Cancer

Abstract

The Hippo pathway remains a central focus in both basic and translational research and is a key modulator of developmental biology. Dysregulation of the pathway is associated with a plethora of human cancers and there are multiple efforts to target key components of the pathway for disease intervention. In this review, we briefly highlight the latest research advances around the core components of the Hippo pathway in cancer. More specifically, we discuss several genetic aberrations of these factors as mechanisms for the development of cancers, including genetic amplification, deletion, and gene fusions. Additionally, we highlight the role of the Hippo pathway in cancer therapy resistance and tumor immunogenicity. Last, we summarize the ongoing efforts to target the pathway in cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trecan.2019.04.001

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 420

Metadata

Authors
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A.
Venue
Trends in Cancer
Publisher
Elsevier BV
Published
2019-05
Volume
5
Issue
5
Pages
297-307
ISSN
  • 2405-8025 (ISSN-L)
  • 2405-8033
OpenAlex
W2946065961
Cited by
420
References
63
FWCI
5.25
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. https://app.cochat.ai/papers/10.1016/j.trecan.2019.04.001
The paper
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A. (2019). Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. Trends in Cancer. https://doi.org/10.1016/j.trecan.2019.04.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.